Ustekinumab for the treatment of moderately to severely active Crohn's disease in children

Ustekinumab is in clinical development for the treatment of moderately to severely active Crohn’s disease in children. Crohn’s disease is an autoimmune disease, where the immune system attacks the body, and in Crohn’s disease this causes ulcers and inflammation in the gut wall. Symptoms include diarrhoea, stomach aches and cramps, blood in the faeces, fatigue and weight loss. The condition has periods of good health, known as remission, and times when it is active, known as flare-ups or relapses. Current treatment options can have considerable toxicity, low efficacy and poor remission rates.